October 20, 2019

October 18, 2019

Subscribe to Latest Legal News and Analysis

CMS Urged To Reverse Obama-Era Biosimilar Reimbursement Policy

A bipartisan congressional effort is underway to convince CMS to reverse its biosimilar reimbursement policy implemented under the Obama administration. We discussed the current reimbursement policy in a March 2016 when CMS initially released the guidance.  CMS implemented the controversial guidance as a final rule in October 2016.

The current policy requires all biosimilars that are related to a reference product to be given a shared Healthcare Common Procedure Coding System (HCPCS) code. For Medicare Part B, reimbursement is then calculated based on the average sales price (ASP) of all of the biosimilars with that HCPCS code plus 6% of their reference product’s ASP.

This policy is controversial because it treats biologics in the same manner as CMS treats generic drugs for reimbursement purposes: all the biosimilars for a reference product will have the same Medicare Part B reimbursement rate. But unlike generics that are chemically produced, biosimilars are not identical to their reference product since they are created from living organisms.  Biosimilars are also not required to treat the same indications as the reference product.  This means that some biosimilars may treat more or fewer conditions than the reference product or other biosimilars and may be more expensive to make than others.  When CMS released its initial guidance, advocacy groups argued that a uniform reimbursement approach would dampen the fledgling biosimilar market and force higher-value biosimilars out of the market (why make better products if you get paid the same as the lesser ones?).

The impact has yet to be seen as there are only two approved biosimilars on the market. With more on the way, it now seems the issue is gaining renewed interest.  Congress itself is stepping in to make the case that each biosimilar should have its own HCPCS code assigned.  This would provide for individual reimbursement calculations for each biosimilar in an effort to encourage a “vibrant” biosimilars market.

With a new administration keen on rolling back regulations, the congressional and advocacy group support for reversal may gain some traction.

©1994-2019 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.

TRENDING LEGAL ANALYSIS


About this Author

Theresa Carnagie, Health Law Attorney, MIntz Levin Law Firm
Member

Theresa counsels health care clients on a variety of transactional, regulatory, and fraud and abuse matters.

Theresa focuses much of her practice on counseling health plans, pharmacy benefit managers, pharmacies, device manufacturers, and distributors on regulatory and compliance matters. Her practice extends to counseling on drug pricing and reimbursement issues, Medicare Advantage and Medicare Part D compliance, and the regulatory requirements under the Affordable Care Act and state health insurance exchanges. Theresa has extensive experience...

202-661-8710
Ellyn Sternfield, Mintz Levin, Law Firm, Washington DC, Health Care Law Attorney
Special Counsel

Ellyn has more than 30 years of legal experience, with an extensive background in the field of government health care enforcement.

Ellyn’s experience enables her to provide valuable insight to clients facing potential state or federal investigations, or who have general compliance concerns. Ellyn currently represents a variety of health care product and service providers in federal and state administrative, civil, and criminal matters around the country. She conducts internal reviews and investigations for clients concerned about potential compliance issues. Ellyn advises clients on...

202-434-7445